<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20160307026950N15</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2019-07-24</date_registration>
      <primary_sponsor>Esfahan University of Medical Sciences</primary_sponsor>
      <public_title>The effects of two different doses dexmedetomidine after Endotracheal intubation</public_title>
      <acronym></acronym>
      <scientific_title>Comparison of the effects of two different doses intranasal Dexmedetomidine on heart rate and blood pressure changes after Laryngoscopy and Endotracheal intubation in patients need of anesthesia before surgery</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2018-03-21</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>90</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/39269</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: Patients are randomly assigned to three groups A, B, C using the Random Allocation computer
software, Blinding description: The drug and placebo are prepared in one form and in the form of a volume in the syringe by the researcher, and the
hemodynamic changes are monitored and recorded, so the attending and the clinical caregiver and the evaluator and data analyser do not understand the type of medication and the investigator deciphers the codes after data analysis.</study_design>
      <phase>3</phase>
      <hc_freetext>Condition 1: Blood pressure. Condition 2: Heart rate.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group A:Initially , informed consent is obtained from the patients. After placing the patients on the operating bed, inclusion of standard monitoring including pulsoximetr , capnograph, electrocardiograph (ECG) and the vital signs are attached . In group A, 1μg∙kg-1 of intranasal dexmedetomidine is given 30 minutes before induction of anesthesia inside both nostrils. Median arterial blood pressure, heart rate, systolic blood pressure and diastolic blood pressure at one, three, five and Ten minutes after intubation are recorded . Intervention 2: Intervention group B:Initially , informed consent is obtained from the patients. After placing the patients on the operating bed, inclusion of standard monitoring including pulsoximetr , capnograph, electrocardiograph (ECG) and the vital signs are attached . In group B, 2μg∙kg-1 of intranasal dexmedetomidine is given 30 minutes before induction of anesthesia inside both nostrils. Median arterial blood pressure, heart rate, systolic blood pressure and diastolic blood pressure at one, three, five and Ten minutes after intubation are recorded . Intervention 3: Control group: Initially , informed consent is obtained from the patients. After placing the patients on the operating bed, inclusion of standard monitoring including pulsoximetr , capnograph, electrocardiograph (ECG) and the vital signs are attached . In group C, normal saline is given 30 minutes before induction of anesthesia inside both nostrils. Median arterial blood pressure, heart rate, systolic blood pressure and diastolic blood pressure at one, three, five and Ten minutes after intubation are recorded .</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is no more information</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Amir Mohammad Ataie</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Hasht Behesht Building, Amin Alley, Bagh-e-Goldaste Street</address>
        <city>Isfahan</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>8145845197</zip>
        <telephone>+98 31 3222 8461</telephone>
        <email>amir.ataie17@gmail.com</email>
        <affiliation>Esfahan University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Behzad Nazemroaya</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Hezar Jarib Street</address>
        <city>Isfahan</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>8146713543</zip>
        <telephone>+98 31 3620 2020</telephone>
        <email>behzad_nazem@med.mui.ac.ir</email>
        <affiliation>Esfahan University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Patients candidate Laryngoscopy and Endotracheal intubation
Patients older than 18 yeras old and younger than 65 years old
Patients with American society of anesthesiology physical status class 1,2 (ASAI,II)</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>65 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Head and neck masses
Airway malformation
Uncontrollable blood pressure(More than 180/110)
History of cardiovascular disease
History of respiratory disease
allergies to the drugs studied
Body Mass Index greater than 30(BMI&gt;30)</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>R03.0</hc_code>
      <hc_code>R00.0</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Elevated blood-pressure reading, without diagnosis of hypertension</hc_keyword>
      <hc_keyword>Tachycardia, unspecified</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Placebo</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group A:Initially , informed consent is obtained from the patients. After placing the patients on the operating bed, inclusion of standard monitoring including pulsoximetr , capnograph, electrocardiograph (ECG) and the vital signs are attached . In group A, 1μg∙kg-1 of intranasal dexmedetomidine is given 30 minutes before induction of anesthesia inside both nostrils. Median arterial blood pressure, heart rate, systolic blood pressure and diastolic blood pressure at one, three, five and Ten minutes after intubation are recorded .</i_keyword>
      <i_keyword>Intervention group B:Initially , informed consent is obtained from the patients. After placing the patients on the operating bed, inclusion of standard monitoring including pulsoximetr , capnograph, electrocardiograph (ECG) and the vital signs are attached . In group B, 2μg∙kg-1 of intranasal dexmedetomidine is given 30 minutes before induction of anesthesia inside both nostrils. Median arterial blood pressure, heart rate, systolic blood pressure and diastolic blood pressure at one, three, five and Ten minutes after intubation are recorded .</i_keyword>
      <i_keyword>Control group: Initially , informed consent is obtained from the patients. After placing the patients on the operating bed, inclusion of standard monitoring including pulsoximetr , capnograph, electrocardiograph (ECG) and the vital signs are attached . In group C, normal saline is given 30 minutes before induction of anesthesia inside both nostrils. Median arterial blood pressure, heart rate, systolic blood pressure and diastolic blood pressure at one, three, five and Ten minutes after intubation are recorded .</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Heart rate changes. Timepoint: Before the intervention, 1 ,3, 5, 10 minutes after laryngoscopy. Method of measurement: Heart monitoring.</prim_outcome>
      <prim_outcome>Systolic blood pressure. Timepoint: Before the intervention, 1 ,3, 5, 10 minutes after laryngoscopy. Method of measurement: Non invasive blood pressure monitor.</prim_outcome>
      <prim_outcome>Diastolic blood pressure. Timepoint: Before the intervention, 1 ,3, 5, 10 minutes after laryngoscopy. Method of measurement: Non invasive blood pressure monitor.</prim_outcome>
      <prim_outcome>Mean arterial pressure. Timepoint: Before the intervention, 1 ,3, 5, 10 minutes after laryngoscopy. Method of measurement: Non invasive blood pressure monitor.</prim_outcome>
      <prim_outcome>Oxygen saturation. Timepoint: Before the intervention, 1 ,3, 5, 10 minutes after laryngoscopy. Method of measurement: Percent with pulse oximeter.</prim_outcome>
      <prim_outcome>Recovery time. Timepoint: From the end of surgery to full consciousness. Method of measurement: Minute with using a chornometer.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Esfahan University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2017-05-28</approval_date>
        <contact_name>Ethics committee of Isfahan University of Medical Sciences</contact_name>
        <contact_address>Hezar Jarib street Isfahan Isfehan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
